Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if the study drug called pembrolizumab could control the
growth or shrink the cancer but it could also cause side effects. Researchers hope to learn
if the study drug will shrink the cancer by half, or prevent it from growing for at least 6
months. Pembrolizumab is an antibody that targets the immune system and activates it to stop
cancer growth and/or kill cancer cells.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Dana-Farber Cancer Institute Huntsman Cancer Institute/ University of Utah M.D. Anderson Cancer Center Merck Sharp & Dohme Corp. University of California, Los Angeles University of California, San Francisco University of Miami